City Therapeutics, Inc. (CTY)
| Market Cap | 1.11B |
| Revenue (ttm) | 14.34M +388.2% |
| Net Income | -87.67M |
| EPS | -15.72 |
| Shares Out | 49.76M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,405,832 |
| Open | 23.00 |
| IPO Price | 18.00 |
| Day's Range | 20.50 - 23.88 |
| 52-Week Range | 18.00 - 23.88 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About CTY
City Therapeutics, Inc. operates as a biopharmaceutical company focused on developing RNA interference (RNAi)-based medicines by engineering RNAi trigger molecules. The company develops RNAi-based medicines using engineered small interfering RNAs (siRNAs) and is building a pipeline of therapeutics targeting diseases across multiple therapeutic areas, including ophthalmologic conditions such as retinal diseases and geographic atrophy. It designs and engineers RNAi trigger molecules, such as smaller size, novel cleavage mechanisms, and tailored t... [Read more]
Financial Performance
Financial StatementsNews
City Therapeutics opened at $23, IPO priced at $18 per share
City Therapeutics (CTY), a clinical-stage biotechnology company that says it is “developing the next generation of RNA interference therapeutics,” priced its upsized initial public offering of 11.11M ...
City Therapeutics indicated to open at $22, IPO priced at $18
11:19 EDT City Therapeutics (CTY) indicated to open at $22, IPO priced at $18
City Therapeutics indicated to open at $20.25, IPO priced at $18
City Therapeutics (CTY), a clinical-stage biotechnology company that says it is “developing the next generation of RNA interference therapeutics,” priced its upsized initial public offering of 11.11M ...
City Therapeutics 11.1M share IPO priced at $18.00
Goldman Sachs, Jefferies, Stifel and Oppenheimer acted as joint book running managers for the offering.
City Therapeutics Announces Pricing of Upsized Initial Public Offering
CAMBRIDGE, Mass., Oct. 15, 2026 (GLOBE NEWSWIRE) -- City Therapeutics, Inc. (Nasdaq: CTY) (“City” or “City Therapeutics”), a clinical-stage biotechnology company developing the next generation of RNA ...
City Therapeutics eyes valuation of up to $956.3 million in US IPO amid biotech listing push
City Therapeutics on Friday said it is targeting a valuation of up to $956.3 million in its US initial public offering, as biotech companies press ahead with listings despite market uncertainty.
Drug developer City Therapeutics files for US IPO
Drug developer City Therapeutics filed for an initial public offering in the US on Thursday.
City Therapeutics IPO Registration Document (S-1)
City Therapeutics has filed to go public with an IPO on the NASDAQ